EarningsQ2 2026 Earnings Report
DE:6A3A Q2 2026 EPS Results
Actual EPS-€0.13
Consensus EPS-€0.17
Beat/MissBeat by +€0.04
One Year Ago EPS-€0.16
DE:6A3A Q2 2026 Revenue Results
Actual Revenue€40.82M
Expected Revenue€34.39M
Beat/MissBeat by +€6.43M
YoY Revenue Growth+116.09%
Earnings Announcement Details
QuarterQ2 2026
Date08/11/2026
TimeBefore Open
Conference CallTuesday, August 11, 2026
DE:6A3A Upcoming Earnings
Autolus Therapeutics's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:6A3A Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong commercial momentum for AUCATZYL with substantial QoQ and YoY revenue growth, a material gross margin inflection to 55%, expanding treatment center footprint (80+ centers) and multiple near-term clinical data catalysts. Financially, operating and net losses narrowed and the company secured a strategic credit facility that, combined with revenue expectations, extends cash runway into mid-2028. Offsetting risks highlighted include continued quarterly losses, higher SG&A related to commercialization and one-time charges, sustained R&D burn, some seasonality/visibility concerns, and contingent tranches of financing tied to milestones. On balance, the positive commercial execution, margin improvement, and funded runway outweigh the remaining operational and financing risks described on the call.Company Guidance
Strong Quarter-over-Quarter Revenue Growth
Net product revenue of $45.7M in Q2 2026, up from $26.2M in Q1 2026 (approximately +74% QoQ) and up from $20.9M in Q2 2025 (approximately +119% YoY). First-half 2026 net revenue reached $71.9M, approaching full-year revenue from the first year of launch.
Increased Full-Year Revenue Guidance
Company raised full-year AUCATZYL net revenue guidance to $140M–$150M (previously $120M–$135M), reflecting stronger-than-expected commercial uptake (guidance increased by about $20M on the low end and $15M on the high end).
Material Gross Margin Improvement
Gross margin improved to 55% in Q2 2026 versus 6% in Q1 2026 and negative in prior 2025 quarters (a step-up of ~49 percentage points QoQ). Management targets a mature ALL gross margin of 65%–70% within ~12–18 months.
Operational & Manufacturing Progress (Nucleus Facility)
Clinical production began at the Nucleus facility in Q2, contributing to improved cost-per-batch economics and lower cost of sales ($20.5M in Q2 2026 vs $24.4M in Q2 2025, ~-16% YoY). Management reported operational efficiency and cost-reduction initiatives drove margin gains.
Commercial Footprint Expansion
Authorized treatment centers exceeded 80 midyear (U.S. distribution broad) with expectation of 90+ centers by year-end; U.K. launch underway with approaching 20 authorized centers by year-end, supporting broader patient access.
Improved Operating and Net Loss Trends
Loss from operations improved to $43.8M in Q2 2026 from $61.2M in Q2 2025 (improvement of $17.4M, ~28% improvement). Net loss narrowed to $39.1M in Q2 2026 from $47.9M in Q2 2025 (improvement of $8.8M, ~18%).
Strategic Financing & Extended Cash Runway
Entered up-to-$250M senior credit facility with Perceptive Advisors: $75M initial draw (closed in July), optional $25M draw for 6 months, plus up to $150M additional tranches tied to revenue milestones. Cash and marketable securities were $201.6M at June 30, 2026 (excluding initial draw). With anticipated net revenues and $100M in credit tranches, management expects runway into Q2 2028.
Robust Pipeline with Multiple Near-Term Catalysts
Several upcoming data readouts cited: CARLYSLE lupus update at ACR (durability/12+ month follow-up), FELIX analyses, AUTO8 (BCMA CD19) initial data by year-end, BOBCAT (progressive MS) initial 12-patient data in early 2027 and expanded 18-patient readout second half 2027, CATULUS pediatric ALL enrollment completion ~end-2027 (pivotal data thereafter), and LUMINA lupus nephritis Phase II data expected in 2028.
DE:6A3A Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed